Updating results

15 results for brentuximab

Sort: Relevance | Date

Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults

Technology appraisal guidance Published October 2017

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory CD30-positive Hodgkin lymphoma in adults

Technology appraisal guidance Published June 2018

Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults

Technology appraisal guidance Published April 2019

Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults

Technology appraisal guidance Published August 2019

Brentuximab vedotin for untreated CD30-positive peripheral T-cell lymphoma ID1586

In development [GID-TA10514] Expected publication date: 12 August 2020

Technology appraisal guidance In development

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma (cHL) in adults

Technology appraisal guidance Published September 2018

Non-Hodgkin's lymphoma

Everything NICE has said on diagnosing and managing non-Hodgkin's lymphoma in adults and young people 16 years and older in an interactive flowchart

NICE Pathway Published July 2016 Last updated October 2019

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults

Technology appraisal guidance Published July 2017

Blood and bone marrow cancers

Everything NICE has said on blood and bone marrow cancers including leukaemia in an interactive flowchart

NICE Pathway Published December 2013 Last updated August 2019

Mogamulizumab for treated mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma [ID1405]

In development [GID-TA10305] Expected publication date: 16 September 2020

Technology appraisal guidance In development

Brentuximab vedotin for untreated advanced Hodgkin lymphoma [1258]

In development [GID-TA10224] Expected publication date: TBC

Technology appraisal guidance In development

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)

This guidance has been updated and replaced by NICE technology appraisal guidance 524.

Technology appraisal guidance Published June 2017

Block scoping reports

This information helps ministers to decide whether or not a technology should be formally referred to NICE for appraisal and whether it should be referred as an MTA or an STA.

Published December 2019 Last updated December 2019

NICE approval for nivolumab provides new treatment for advanced blood cancer

People with an advanced type of blood cancer will benefit from nivolumab on the NHS following approval by NICE.

News Published July 2017 Last updated July 2017

Hundreds of people with blood cancer given more treatment options after NICE recommends three drugs

NICE has recommended three blood cancer drugs, brentuximab vedotin, midostaurin and arsenic trioxide be made available on the NHS.

News Published May 2018 Last updated May 2018